Genetic markers in clinically well defined patients with ulcerative colitis (UC)

Clinical and Experimental Immunology

Volumn 115, Issue 2, 1999, Pages 294-300

  Bouma, G ^a,d   Crusius, J B A ^a   Garcia Gonzalez M A ^a   Meijer, B U G A ^a   Hellemans, H P R ^a   Hakvoort, R J ^a   Schreuder, G M Th ^a,c   Kostense, P J ^a,b   Meuwissen, S G M ^a   Pena A S ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cytokines polymorphism; Heterogeneity; HLA; Ulcerative colitis

Indexed keywords

HLA DR1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENETIC RISK; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MARKER GENE; NEWBORN; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CHILD; COLITIS, ULCERATIVE; CYTOKINES; FEMALE; GENE FREQUENCY; GENETIC MARKERS; HAPLOTYPES; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032953803     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00797.x     Document Type: Article

References (44)

1. 1 Satsangi J, Jewell DP, Rosenberg WMC, Bell JI. Genetics of inflammatory bowel disease. Gut 1994; 35:696-700.
2. 2 Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379:821-3.
3. 3 Satsangi J, Parkes M, Louis E et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genetics 1996; 4:199-202.
4. 4 Ohmen JD, Yang HY, Yamamoto KK et al. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. Hum Mol Gen 1996; 5:1679-83.
5. 5 Sugimura K, Asakura H, Mizuki M et al. Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. Hum Immunol 1993; 36:112-8.
6. 6 Masuda H, Nakamura Y, Tanaka T, Hayakawa S. Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol 1994; 89:1957-62.
7. 7 Futami S, Aoyama N, Honsako Y et al. HLA-DRB*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci 1995; 40:814-8.
8. 8 Toyoda H, Wang SJ, Yang HY et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993; 104:741-8.
9. 9 Caruso C, Palmeri P, Oliva L, Orlando A, Cottone M. HLA antigens in ulcerative colitis, a study in the Sicilian population. Tissue Antigens 1985; 25:47-49.
10. 10 Bouma G. Oudkerk Pool M, Crusius JBA et al. Evidence for genetic heterogeneity in IBD. HLA genes in the predisposition to suffer from ulcerative colitis and Crohn's disease. Clin Exp Immunol 1997; 109:175-9.
11. 11 De la Concha EG, Fernandez-Arquero M, Santa-Cruz S et al. Positive and negative associations of distinct HLA-DR2 subtypes with ulcerative colitis (UC). Clin Exp Immunol 1997; 108:392-5.
12. 12 Satsangi J, Welsh KI, Bunce M et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347:1212-7.
13. 13 Mansfield JC, Holden H, Tarlow JK et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106:637-42.
14. 14 Bioque G, Bouma G, Crusius JBA et al. Evidence for genetic heterogeneity in IBD. 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8:105-10.
15. 15 Bioque G, Crusius JBA, Koutroubakis I et al. Allelic polymorphism in IL-1β and IL-1 receptor antagonist (IL-1RA) genes in inflammatory bowel disease. Clin Exp Immunol 1995; 102:379-83.
16. 16 van Dullemen HM, van Deventer SJH, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-35.
17. 17 Bouma G, Xia B, Crusius JBA et al. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996; 103: 391-6.
18. 18 Louis E, Satsangi J, Roussomoustakaki M et al. Cytokine gene polymorphism in inflammatory bowel disease. Gut 1996; 39:705-10.
19. 19 Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis. A study on the course and prognostic factors. Scand J Gastroenterol 1996; 31:260-6.
20. 20 Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112:1845-63.
21. 21 Bouma G, Poen C, García González MA et al. HLA-DRB1*03, but not the TNFalpha -308 promoter gene polymorphism confers protection against fistulising Crohn's disease. Immunogenetics 1998; 47:451-5.
22. 22 Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24 (Suppl. 170): 2-6.
23. 23 Verduyn W, Doxiadis IIN, Anholts J et al. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologiec HLA-DR typing of organ donors in Eurotransplant. Hum Immunol 1993; 37:59-67.
24. 24 Mehra NK, Verduyn W, Taneja V, Drabbels J, Singh SPN, Giphart MJ. Analysis of HLA-DR2-associated polymorphisms by oligonucleotide hybridization in an Asian Indian population. Hum Immmol 1991; 32:246-53.
25. 25 D'Alfonso S, Momigliano Richiardi P. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994; 39:150-4.
26. 26 Messer G, Spengler U, Jung MC et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: a Ncol polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991; 173:209-19.
27. 27 Ferencik S, Lindemann M, Horsthemke B, Grosse-Wilde H. A new-restriction fragment length polymorphism of the human TNF-beta gene detected by AspHI digest. Eur J Immunogenet 1992; 19:425-30.
28. 28 Crusius JBA, Bing X, Mulder CJJ, Mearin ML, Peña AS. Relevance of haplotypes in the TNF region in celiac disease. Eur Cytok Network 1994; 2:168.
29. 29 Mehta C, Patel N. StatXact-Turbo. Statistical software for exact nonparametric inference. User manual. Cambridge MA: CYTEL Software Corporation, 1992.
30. 30 Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273:1516-7.
31. 31 Duerr RH, Chensy LJ. Associations between HLA-DR alleles and subsets of ulcerative colitis defined by extent of colitis [Abstract]. Gastroenterology 1997; 112:A963.
32. 32 De la Concha EG, Arroyo R, Crusius JBA et al. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmmol 1997; 80:172-8.
33. 33 Yang H, Rotter JI, Toyoda H et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and sub-clinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92:1080-4.
34. 34 Bendtzen K, Morling N, Fomsgaard A et al. Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol 1988; 28:599-606.
35. 35 Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87:1233-7.
36. 36 Bouma G, Crusius JBA, Oudkerk Pool M et al. Secretion of tumor necrosis factor alpha and lymphotoxin alpha in relation to TNF gene polymorphisms and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1995; 43: 456-63.
37. 37 Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcription activation. Proc Natl Acad Sci USA 1997; 94:3195-9.
38. 38 Mazlam MZ, Hodgson HJF. Peripheral blood monocyte production and acute phase response in inflammatory bowel disease. Gut 1992; 33:773-8.
39. 39 Bouma G, Oudkerk Pool M, Scharenberg JGM et al. Differences in the intrinsic capacity of T-cells to produce the cytokines tumour necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995; 30:1095-100.
40. 40 Derckx B, Taminiau J, Radema S et al. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993; 342:173-4.
41. 41 Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349:521-4.
42. 42 Baert F, D'Haens G, Geboes K, Ectors N, Rutgeerts P. TNF-alpha antibody therapy causes a fast and dramatic decrease of histologic colonic inflammation in Crohn's disease but not in ulcerative colitis [Abstract]. Gastroenterology 1996; 110:A859.
43. 43 Sands BE, Podolsky DK, Tremaine WJ et al. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC) [Abstract]. Gastroenterology 1996; 110:A1008.
44. 44 Evans RC, Clark L, Heath P, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNF alpha antibody cdp571 [Abstract]. Gastroenterology 1996; 110:A905.